AndreaBozzo/ceres-open-data-index huggingface dataset:
Respiratory Conditions Treated in the Emergency Department

Methods for Creating Respiratory Conditions: The International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) discharge diagnostic codes listed in the Acute Respiratory Index (ARI) were used as a starting point to define respiratory conditions. For a list of diagnostic codes included in the ARI metric, visit the [Acute Respiratory Illness Technical Brief]. These codes were further refined to exclude pathogen-specific codes and, when appropriate, were grouped using ICD-10-CM parent codes and [Clinical Classifications Software Refined (CCSRs)] categories, which organize ICD-10-CM codes into 14 clinically meaningful categories. Short codes listed capture all codes underneath them (e.g., J09 includes J09.X1–J09.X9). Findings for each of the 14 condition categories were analyzed by age group. Source: National Syndromic Surveillance Program (NSSP) The NSSP is a collaboration among CDC, local and state health departments, and private sector partners. Together, these partners collect, share, and analyze automated electronic healthcare data in near-real time. National data include emergency departments in all 50 states, the District of Columbia, and Guam. View the [Coverage Map].
RESP-LENS

During the 2022-23 and 2023-24 respiratory illness seasons, the Respiratory Virus Laboratory Emergency Department Network Surveillance (RESP-LENS) system gathered electronic health record (EHR) data from nearly 100 hospitals associated with 24 participating sites located in 20 states and the District of Columbia. There was at least one site in each of the 10 Health and Human Services (HHS) regions. RESP-LENS collected reports of emergency department (ED) visits for acute respiratory illness (ARI) and corresponding viral testing results for SARS-CoV-2 (the virus that causes COVID-19), influenza (flu), and respiratory syncytial virus (RSV). Sites reported data for an average of approximately 77,000 ED visits weekly, of which 11,000 were associated with ARI and 4,000 of those were in children younger than 18 years. Between May 2023 and August 2024, these data were posted to CDC's RESP-LENS public dashboard, showing number tested, number positive, and percent positive for each of the three viruses mentioned, by virus, region, and age group. Due to budget constraints, RESP-LENS was not funded beyond the end of the 2024 fiscal year. RESP-LENS served as a valuable tool for public health and health care professionals and allowed users to visualize and understand trends in virus circulation, estimate disease burden, respond to outbreaks, and inform decisions and strategies for protecting public health.
Reduced Access to Care During COVID-19

The Research and Development Survey (RANDS) is a platform designed for conducting survey question evaluation and statistical research. RANDS is an ongoing series of surveys from probability-sampled commercial survey panels used for methodological research at the National Center for Health Statistics (NCHS). RANDS estimates are generated using an experimental approach that differs from the survey design approaches generally used by NCHS, including possible biases from different response patterns and sampling frames as well as increased variability from lower sample sizes. Use of the RANDS platform allows NCHS to produce more timely data than would be possible using traditional data collection methods. RANDS is not designed to replace NCHS’ higher quality, core data collections. Below are experimental estimates of reduced access to healthcare for three rounds of RANDS during COVID-19. Data collection for the three rounds of RANDS during COVID-19 occurred between June 9, 2020 and July 6, 2020, August 3, 2020 and August 20, 2020, and May 17, 2021 and June 30, 2021. Information needed to interpret these estimates can be found in the Technical Notes. RANDS during COVID-19 included questions about unmet care in the last 2 months during the coronavirus pandemic. Unmet needs for health care are often the result of cost-related barriers. The National Health Interview Survey, conducted by NCHS, is the source for high-quality data to monitor cost-related health care access problems in the United States. For example, in 2018, 7.3% of persons of all ages reported delaying medical care due to cost and 4.8% reported needing medical care but not getting it due to cost in the past year. However, cost is not the only reason someone might delay or not receive needed medical care. As a result of the coronavirus pandemic, people also may not get needed medical care due to cancelled appointments, cutbacks in transportation options, fear of going to the emergency room, or an altruistic desire to not be a burden on the health care system, among other reasons. The Household Pulse Survey (https://www.cdc.gov/nchs/covid19/pulse/reduced-access-to-care.htm), an online survey conducted in response to the COVID-19 pandemic by the Census Bureau in partnership with other federal agencies including NCHS, also reports estimates of reduced access to care during the pandemic (beginning in Phase 1, which started on April 23, 2020). The Household Pulse Survey reports the percentage of adults who delayed medical care in the last 4 weeks or who needed medical care at any time in the last 4 weeks for something other than coronavirus but did not get it because of the pandemic. The experimental estimates on this page are derived from RANDS during COVID-19 and show the percentage of U.S. adults who were unable to receive medical care (including urgent care, surgery, screening tests, ongoing treatment, regular checkups, prescriptions, dental care, vision care, and hearing care) in the last 2 months. Technical Notes: https://www.cdc.gov/nchs/covid19/rands/reduced-access-to-care.htm#limitations
Rates of TBI-related Emergency Department Visits, Hospitalizations, and Deaths - United States, 2001 – 2010

In general, total combined rates for traumatic brain injury (TBI)-related emergency department (ED) visits, hospitalizations and deaths have increased over the past decade. Total combined rates of TBI-related hospitalizations, ED visits, and deaths climbed slowly from a rate of 521.0 per 100,000 in 2001 to 615.7 per 100,000 in 2005. The rates then dipped to 595.1 per 100,000 in 2006 and 566.7 per 100,000 in 2007. The rates then spiked sharply in 2008 and continued to climb through 2010 to a rate of 823.7 per 100,000. Total combined rates of TBI-related hospitalizations, ED visits, and deaths are driven in large part by the relatively high number of TBI-related ED visits. In comparison to ED visits, the overall rates of TBI-related hospitalizations remained relatively stable changing from 82.7 per 100,000 in 2001 to 91.7 per 100,000 in 2010. TBI-related deaths also decreased slightly over time from 18.5 per 100,000 in 2001 to 17.1 per 100,000 in 2010. Note that the axis scale for TBI-related deaths appears to the right of the chart and differs from TBI-related hospitalizations and ED visits.Go to http://www.cdc.gov/traumaticbraininjury/data/index.html to view more TBI data & statistics.
Rates of TBI-related Emergency Department Visits, Hospitalizations, and Deaths by Sex - United States, 2001 – 2010

Overall rates of TBI climbed slowly from 2001 through 2007, then spiked sharply in 2008 and continued to climb through 2010. The increase in TBI rates in 2008 was much sharper for men (nearly 40% increase) than for women (20% increase). In 2007, overall rates of TBI were 26% higher in men compared to women. In 2008, that gap began to widen, reaching 61% in 2009 before narrowing to 29% in 2010. Rates of overall TBI are largely driven by rates of TBI-related ED visits.
Rates of TBI-related Deaths by Age Group - United States, 2001 - 2010

Changes in the rates of TBI-related deaths vary depending on age. For persons 44 years of age and younger, TBI-related deaths decreased between the periods of 2001-2002 and 2009-2010. Rates for age groups 45-64 years of age remained stable for this same ten-year period. For persons 65 years and older, rates of TBI-related deaths increased during this time period, from 41.2 to 45.2 deaths per 100,000.Go to http://www.cdc.gov/traumaticbraininjury/data/index.html to view more TBI data & statistics.Source: http://www.cdc.gov/traumaticbraininjury/data/rates_deaths_byage.html
Rates and Trends in Hypertension-related Cardiovascular Disease Mortality Among US Adults (35+) by County, Age Group, Race/Ethnicity, and Sex – 2000-2019

This dataset documents rates and trends in local hypertension-related cardiovascular disease (CVD) death rates. Specifically, this report presents county (or county equivalent) estimates of hypertension-related CVD death rates in 2000-2019 and trends during two intervals (2000-2010, 2010-2019) by age group (ages 35–64 years, ages 65 years and older), race/ethnicity (non-Hispanic American Indian/Alaska Native, non-Hispanic Asian/Pacific Islander, non-Hispanic Black, Hispanic, non-Hispanic White), and sex (female, male). The rates and trends were estimated using a Bayesian spatiotemporal model and a smoothed over space, time, and demographic group. Rates are age-standardized in 10-year age groups using the 2010 US population. Data source: National Vital Statistics System.
Rates and Trends in Heart Disease and Stroke Mortality Among US Adults (35+) by County, Age Group, Race/Ethnicity, and Sex – 2000-2019

This dataset documents rates and trends in heart disease and stroke mortality. Specifically, this report presents county (or county equivalent) estimates of heart disease and stroke death rates in 2000-2019 and trends during two intervals (2000-2010, 2010-2019) by age group (ages 35–64 years, ages 65 years and older), race/ethnicity (non-Hispanic American Indian/Alaska Native, non-Hispanic Asian/Pacific Islander, non-Hispanic Black, Hispanic, non-Hispanic White), and sex (women, men). The rates and trends were estimated using a Bayesian spatiotemporal model and a smoothed over space, time, and demographic group. Rates are age-standardized in 10-year age groups using the 2010 US population. Data source: National Vital Statistics System.
Provisional Drug Overdose Deaths by Urban/Rural Classification Scheme for 12 month-ending December 2018-December 2020

National provisional drug overdose deaths by month and 2013 NCHS Urban–Rural Classification Scheme for Counties. Drug overdose deaths are identified using underlying cause-of-death codes from the Tenth Revision of ICD (ICD–10): X40–X44 (unintentional), X60–X64 (suicide), X85 (homicide), and Y10–Y14 (undetermined). Deaths are based on the county of residence in the United States. Death counts provided are for “12-month ending periods,” defined as the number of deaths occurring in the 12-month period ending in the month indicated. Estimates for 2020 are based on provisional data. Estimates for 2018 and 2019 are based on final data. For more information on NCHS urban-rural classification, see: https://www.cdc.gov/nchs/data/series/sr_02/sr02_166.pdf
Provisional drug overdose death counts for specific drugs

This data presents counts of provisional drug overdose deaths by selected drugs and U.S. Department of Health and Human Services (HHS) public health regions, based on provisional mortality data from the National Vital Statistics System. This data is limited to drug overdose deaths with an underlying cause of death assigned to International Statistical Classification of Diseases, 10th Revision (ICD-10) code numbers X40-X44 (unintentional), X60-X64 (suicide), X85 (homicide), or Y10-Y14 (undetermined intent). Specific drugs were identified using methods for searching literal text from death certificates. The provisional data are based on a current flow of mortality data and include reported 12 month-ending provisional counts of drug overdose deaths by jurisdiction of occurrence and specified drug. Provisional drug overdose death counts presented on this page are for “12-month ending periods,” defined as the number of deaths occurring in the 12-month period ending in the month indicated. For example, the 12-month ending period in June 2022 would include deaths occurring from July 1, 2021, through June 30, 2022. Evaluation of trends over time should compare estimates from year to year (June 2021 and June 2022), rather than month to month, to avoid overlapping time periods. It is important to note that the data represent counts of deaths, and not mortality ratios or rates, which are the standard measure used to compare groups, and therefore should not be used to determine populations at disproportionate risk of drug overdose death.
Provisional COVID-19 Deaths: Distribution of Deaths by Race and Hispanic Origin

Effective September 27, 2023, this dataset will no longer be updated. Similar data are accessible from wonder.cdc.gov. This data file contains the following indicators that can be used to illustrate potential differences in the burden of deaths due to COVID-19 according to race and ethnicity: count of COVID-19 deaths, distribution of COVID-19 deaths, unweighted distribution of population, and weighted distribution of population.
Provisional COVID-19 Deaths by Week and Urbanicity

Effective September 27, 2023, this dataset will no longer be updated. Similar data are accessible from wonder.cdc.gov. Provisional COVID-19 deaths by urbanicity and week. Deaths are based on the county of occurrence in the United States. Urbanicity is defined as metropolitan and non-metropolitan, based on the 2013 National Center for Health Statistics (NCHS) Urban-Rural Classification Scheme for Counties. Counties are classified as “metropolitan” if they are large central metro, large fringe metro, medium metro or small metro; and “non-metropolitan” if micropolitan or non-core.
Provisional COVID-19 Deaths by Week and County Social Vulnerability Index

Effective September 27, 2023, this dataset will no longer be updated. Similar data are accessible from wonder.cdc.gov. Deaths involving COVID-19 reported to NCHS by week and county Social Vulnerability Index (SVI) in the United States. SVI scores are from CDC/ASTDR's Geospatial Research, Analysis & Service Program 2018 database. These scores range from 0 to 1, and categorized as low (0-0.333), moderate (0.334-0.666) or high (0.667-1). More information on SVI can be found here: https://www.atsdr.cdc.gov/placeandhealth/svi/index.html
Provisional COVID-19 Deaths by HHS Region, Race, and Age

Effective September 27, 2023, this dataset will no longer be updated. Similar data are accessible from wonder.cdc.gov. Deaths involving COVID-19 reported to NCHS by time-period, HHS region, race and Hispanic origin, and age group. United States death counts include the 50 states, plus the District of Columbia and New York City. The ten (10) United States Department of Health and Human Services (HHS) regions include the following jurisdictions. Region 1: Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, Vermont; Region 2: New Jersey, New York, New York City, Puerto Rico; Region 3: Delaware, District of Columbia, Maryland, Pennsylvania, Virginia, West Virginia; Region 4: Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee; Region 5: Illinois, Indiana, Michigan, Minnesota, Ohio, Wisconsin; Region 6: Arkansas, Louisiana, New Mexico, Oklahoma, Texas; Region 7: Iowa, Kansas, Missouri, Nebraska; Region 8: Colorado, Montana, North Dakota, South Dakota, Utah, Wyoming; Region 9: Arizona, California, Hawaii, Nevada; Region 10: Alaska, Idaho, Oregon, Washington.
Provider Relief Fund COVID-19 Nursing Home Quality Incentive Program

The bipartisan CARES Act; and the Paycheck Protection Program and Health Care Enhancement Act (PPPHCEA); and the Coronavirus Response and Relief Supplemental Appropriations (CRRSA) Act provided $178 billion in relief funds to hospitals and other healthcare providers on the front lines of the coronavirus response. The Department of Health and Human Services through the Health Resources and Services Administration is allocating $2 billion in incentive payments to nursing home facilities that reduce both COVID-19 infection rates relative to their county and mortality rates against a national benchmark.
Provider Relief Fund COVID-19 High-Impact Payments

The bipartisan CARES Act; the Paycheck Protection Program and Health Care Enhancement Act (PPPHCEA); and the Coronavirus Response and Relief Supplemental Appropriations (CRRSA) Act provided $178 billion in relief funds to hospitals and other healthcare providers on the front lines of the coronavirus response. The Department of Health and Human Services through the Health Resources and Services Administration is distributing two rounds of payments to hospitals in High Impact areas for positive COVID-19 admissions. In the first round of the High Impact Allocation, $12 billion was distributed to nearly 400 hospitals who provided inpatient care for 100 or more COVID-19 patients through April 10, 2020. $2 billion of these payments was distributed to these hospitals based on their Medicare disproportionate share and uncompensated care payments. In the second round of funding, $10 billion will be distributed to hospitals having over 161 COVID-19 admissions between January 1 and June 10, 2020.
Prevalence of Selected Measures Among Adults Aged 20 and Over: United States, 1999-2000 through 2017-2018

This data represents the age-adjusted prevalence of high total cholesterol, hypertension, and obesity among US adults aged 20 and over between 1999-2000 to 2017-2018. Notes: * All estimates are age adjusted by the direct method to the U.S. Census 2000 population using age groups 20–39, 40–59, and 60 and over. Definitions Hypertension: Systolic blood pressure greater than or equal to 130 mmHg or diastolic blood pressure greater than or equal to 80 mmHg, or currently taking medication to lower high blood pressure High total cholesterol: Serum total cholesterol greater than or equal to 240 mg/dL. Obesity: Body mass index (BMI, weight in kilograms divided by height in meters squared) greater than or equal to 30. Data Source and Methods Data from the National Health and Nutrition Examination Surveys (NHANES) for the years 1999–2000, 2001–2002, 2003–2004, 2005–2006, 2007–2008, 2009–2010, 2011–2012, 2013–2014, 2015–2016, and 2017–2018 were used for these analyses. NHANES is a cross-sectional survey designed to monitor the health and nutritional status of the civilian noninstitutionalized U.S. population. The survey consists of interviews conducted in participants’ homes and standardized physical examinations, including a blood draw, conducted in mobile examination centers.
Preliminary Estimates of Visits to Health Centers in the United States, January 2022-December 2025

The National Ambulatory Medical Care Survey (NAMCS) Health Center Component, conducted by the National Center for Health Statistics (NCHS), collects annual data on visits to health centers to describe patterns of utilization and provision of ambulatory care delivery in the United States. Data are collected from federally qualified health centers (FQHCs) and FQHC look-alikes from all 50 U.S. states and the District of Columbia and are used to develop nationally representative estimates. The data include preliminary, biannual counts and rates of health center visits from January 2022-December 2025 by medical diagnosis chapters, maternal and reproductive health-related diagnoses, mental health disorders, and respiratory conditions, stratified by selected patient characteristics. Estimates are split into biannual time periods (January to June, and July to December) and are considered preliminary, meaning they may differ from final estimates.
TABLE III. Deaths in 122 U.S. cities

TABLE III. Deaths in 122 U.S. cities – 2016. 122 Cities Mortality Reporting System — Each week, the vital statistics offices of 122 cities across the United States report the total number of death certificates processed and the number of those for which pneumonia or influenza was listed as the underlying or contributing cause of death by age group (Under 28 days, 28 days –1 year, 1-14 years, 15-24 years, 25-44 years, 45-64 years, 65-74 years, 75-84 years, and ≥ 85 years). FOOTNOTE: U: Unavailable. —: No reported cases. * Mortality data in this table are voluntarily reported from 122 cities in the United States, most of which have populations of 100,000 or more. A death is reported by the place of its occurrence and by the week that the death certificate was filed. Fetal deaths are not included. † Pneumonia and influenza. § Total includes unknown ages.
Post-COVID Conditions

As part of an ongoing partnership with the Census Bureau, the National Center for Health Statistics (NCHS) recently added questions to assess the prevalence of post-COVID-19 conditions (long COVID), on the experimental Household Pulse Survey. This 20-minute online survey was designed to complement the ability of the federal statistical system to rapidly respond and provide relevant information about the impact of the coronavirus pandemic in the U.S. Data collection began on April 23, 2020. Beginning in Phase 3.5 (on June 1, 2022), NCHS included questions about the presence of symptoms of COVID that lasted three months or longer. Phase 3.5 will continue with a two-weeks on, two-weeks off collection and dissemination approach. Estimates on this page are derived from the Household Pulse Survey and show the percentage of adults aged 18 and over who a) as a proportion of the U.S. population, the percentage of adults who EVER experienced post-COVID conditions (long COVID). These adults had COVID and had some symptoms that lasted three months or longer; b) as a proportion of adults who said they ever had COVID, the percentage who EVER experienced post-COVID conditions; c) as a proportion of the U.S. population, the percentage of adults who are CURRENTLY experiencing post-COVID conditions. These adults had COVID, had long-term symptoms, and are still experiencing symptoms; d) as a proportion of adults who said they ever had COVID, the percentage who are CURRENTLY experiencing post-COVID conditions; and e) as a proportion of the U.S. population, the percentage of adults who said they ever had COVID.
Population-Weighted Ultraviolet Irradiance, 2004-2015

This dataset provides data at the county level for the contiguous United States. It includes daily Ozone Monitoring Instrument (OMI) Population-Weighted Ultraviolet (UV) irradiance data from October 2004-2015 provided by the Environmental Remote Sensing group at the Rollins School of Public Health at Emory University. Please refer to the metadata attachment for more information. These data are used by the CDC's National Environmental Public Health Tracking Network to generate sunlight and UV measures. Learn more about sunlight and UV on the Tracking Network's website: https://ephtracking.cdc.gov/showUVLanding. By using these data, you signify your agreement to comply with the following requirements: 1. Use the data for statistical reporting and analysis only. 2. Do not attempt to learn the identity of any person included in the data and do not combine these data with other data for the purpose of matching records to identify individuals. 3. Do not disclose of or make use of the identity of any person or establishment discovered inadvertently and report the discovery to: trackingsupport@cdc.gov. 4. Do not imply or state, either in written or oral form, that interpretations based on the data are those of the original data sources and CDC unless the data user and data source are formally collaborating. 5. Acknowledge, in all reports or presentations based on these data, the original source of the data and CDC. 6. Suggested citation: Centers for Disease Control and Prevention. National Environmental Public Health Tracking Network. Web. Accessed: insert date. www.cdc.gov/ephtracking. Problems or Questions? Email trackingsupport@cdc.gov.